Alnylam Pharmaceuticals Announces Positive HELIOS-B Phase 3 Results for AMVUTTRA® (Vutrisiran), Showing Reduced GI Events in ATTR-CM Patients
I'm PortAI, I can summarize articles.
Alnylam Pharmaceuticals Inc. announced positive results from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), showing a 37-49% reduction in gastrointestinal adverse events compared to placebo in ATTR-CM patients. The findings, presented at the HFSA Annual Scientific Meeting 2025, support the safety and efficacy of vutrisiran and its recent approvals in multiple regions, including the US and EU.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments